Notably, in one case report involving a 63-year-old male NSCLC patient with KIF5B-RET fusion, a 10.8 mm intracranial lesion at baseline reduced by 40.7% after 4 weeks and by 56.5% after 12 weeks of treatment with SY-5007 at 160 mg BID (Supplementary Fig. 4), highlighting the promising intracranial efficacy of SY-5007. This evidence concerns the gene KIF5B and non-small cell lung carcinoma.